Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: A retrospective analysis

Community Oncology

Volumn 7, Issue 7, 2010, Pages 297-308

  Gregory, Stephanie A ^a   Schwartzberg, Lee S ^b   Mo, May ^c   Sierra, Jorge ^d   Vogel, Charles ^e  

^a RUSH UNIVERSITY   (United States)

^b WEST CLINIC   (United States)

^c AMGEN INC   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Cancer Research Network Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ARTICLE; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HODGKIN DISEASE; HUMAN; INCIDENCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PAIN ASSESSMENT; RETROSPECTIVE STUDY; SARCOMA; TUMOR CLASSIFICATION;

EID: 77956132066     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70402-8     Document Type: Article

References (43)

1. Kwak LW, Halpern J, Olshen RA, Horning SJ: Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
2. Lyman GH, Dale DC, Crawford J: Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531.
3. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
4. Link BK, Budd GT, Scott S, et al: Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001;92:1354-1367.
5. National Comprehensive Cancer Network clinical practice guidelines in oncology. Myeloid growth factors. V1. 2010. www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. 2010. Accessed March 23, 2010.
6. Neupogen [package insert]. Thousand Oaks, CA: Amgen Inc.; 2009.
7. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.
8. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-1422.
9. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-324.
10. Yang BB. Integration of pharmacokinetics and pharmacodynamics into the drug development of pegfilgrastim, a pegylated protein. In: Meibohm B, ed. Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development: Weinheim, Germany: WILEY-VCH Verlag GmbH & Co, KGaA; 2006:373-393.
11. Neulasta [package Insert]. Thousand Oaks, CA: Amgen Inc.; 2009.
12. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
13. Holmes FA, Jones SE, O'Shaughnessy J, et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-909.
14. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with highrisk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731.
15. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184.
16. Kirshner JJ, Hickok J, Hofman M: Pegfilgrastim-induced bone pain: incidence, risk factors, and management in a community practice. Commun Oncol 2007;4:455-459.
17. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T: Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391-398.
18. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G: Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;23:2283-2295.
19. Aldairy Y, Nguyen PL, Jatoi A: Bone pain from granulocyte colony stimulating factor: does clinical trial sponsorship by a pharmaceutical company influence its reporting? Eur J Cancer Care 2009;Aug 25 [Epub ahead of print]
20. Burris HA, Belani CP, Kaufman PA, et al: Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010:6:133-140.
21. Molineux G, Kinstler O, Briddell B, et al: A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-1734.
22. Yang BB, Kido A, Salfi M, Swan S, Sullivan JT: Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. J Clin Pharmacol 2008;48:1025-1031.
23. Spunt SL, Irving H, Frost J, et al: Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 2010;28:1329-1336.
24. Willis F, Woll P, Theti D, et al: Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. Bone Marrow Transplant 2009;43:927-934.
25. Russell N, Mesters R, Schubert J, et al: A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008;93:405-412.
26. Sierra J, Szer J, Kassis J, et al: A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008;8:195.
27. Ozer H, Mirtsching B, Rader M, et al: Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007;12:484-494.
28. De Boer RH, Patterson W, Beith J, Rocchi L, Beer F, Lewis C: Delivery of adjuvant dose dense doxorubicin + cyclophosphamide →paclitaxel to early-stage breast cancer patients with pegfilgrastim and darbepoetin alfa support-interim results from an Australian phase II study [A3074]. 30th Annual San Antonio Breast Cancer Society; San Antonio, Tex; December 13-16, 2007.
29. Grigg A, Solal-Celigny P, Hoskin P, et al: Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1503-1508.
30. Lopez A, de Sevilla AF, Castaigne S, et al: Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomised phase II study. Blood 2004;104(11):3311.
31. Vose JM, Crump M, Lazarus H, et al: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-519.
32. Johnston E, Crawford J, Blackwell S, et al: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-2528.
33. Romieu G, Clemens M, Mahlberg R, et al: Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 2007;64:64-72.
34. Hecht JR, Pillai M, Gollard R, et al: A randomized placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clinical Colorectal Cancer 2010;9:95-101.
35. Smith F, Kandahari M, Tomita D, Green J, Dansey R, Crawford J: Neutropenia and anxiety in advanced non-small cell lung cancer (NSCLC) patients: initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenia complications. J Clin Onc 2005;23(16S):A8173.
36. Balducci L, Al-Halawani H, Charu V, et al: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12:1416-1424.
37. Mattioli R, Gridelli C, Castellanos J, et al: Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. Clin Transl Oncol 2009;11:842-848.
38. George S, Yunus F, Case D, et al: Fixeddose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1691-1696.
39. Wolf M, Bentley M, Marlton P, et al: Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:2344-2350.
40. Engert A, Bredenfeld H, Döhner H, et al: Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica 2006;91:546-549.
41. Pirker R, Ulsperger E, Messner J, et al: Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive smallcell lung cancer. Lung 2006;184:279-285.
42. Schwartzberg LS, Mo M, Harms R, Vogel CL: Reported bone pain in patients with breast cancer receiving taxane-based chemotherapy in clinical trials of pegfilgrastim. Presented at: San Antonio Breast Cancer Symposium; San Antonio, Texas; December 9-13, 2009.
43. Sierra J, Harms R, Mo M, Vogel CL: Evaluation of reported bone pain in patients (pts) receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol 2009;27(15S):A9621.